# Pre-Approval Access to Pimodivir for the Treatment of Patients With H7N9 Influenza A Infection

> **NCT03834376** · — · NO_LONGER_AVAILABLE · sponsor: **Janssen Research & Development, LLC**

## Conditions studied

- H7N9 Subtype of Influenza A Virus

## Interventions

- **DRUG:** Pimodivir

## Key facts

- **NCT ID:** NCT03834376
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2020-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03834376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03834376, "Pre-Approval Access to Pimodivir for the Treatment of Patients With H7N9 Influenza A Infection". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03834376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*